De-escalated Induction Treatment in Primary CNS Lymphoma
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This phase III study investigates if a de-escalated induction treatment in newly diagnosed
primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free
survival.
Phase:
Phase 3
Details
Lead Sponsor:
Klinikum Stuttgart
Collaborators:
German Federal Ministry of Education and Research University Hospital Freiburg